IMPDH2 Cancer Research Results

IMPDH2, inosine monophosphate dehydrogenase 2: Click to Expand ⟱
Source:
Type:
IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. IMPDH2 expression has been found to be vastly dysregulated in several cancer types, promoting pro-tumorigenic phenotypes and leading to an elevated IMPDH2/IMPDH1 ratio.

Many cancers have high levels of IMPDH2 and is associated with increased tumor proliferation, aggressiveness, and poorer overall survival. Its expression often correlates with a more aggressive tumor phenotype.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
76- QC,    Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy
- in-vitro, Pca, PC3
aSmase↝, Diablo↑, Fas↓, Hsc70↓, Hif1a↓, Mcl-1↓, HSP90↓, FLT4↓, EphB4↓, DNA-PK↓, PARP1↓, ATM↓, XIAP↝, PLC↓, GnT-V↝, heparanase↝, NM23↑, CSR1↑, SPP1↓, DNMT1↓, HDAC4↓, CXCR4↓, β-catenin/ZEB1↓, FBXW7↝, AMACR↓, cycD1/CCND1↓, IGF-1R↓, IMPDH1↓, IMPDH2↓, HEC1↓, NHE1↓, NOS2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

XIAP↝, 1,  

Core Metabolism/Glycolysis ⓘ

AMACR↓, 1,  

Cell Death ⓘ

aSmase↝, 1,   CSR1↑, 1,   Diablo↑, 1,   Fas↓, 1,   Mcl-1↓, 1,  

Transcription & Epigenetics ⓘ

SPP1↓, 1,  

Protein Folding & ER Stress ⓘ

Hsc70↓, 1,   HSP90↓, 1,  

DNA Damage & Repair ⓘ

ATM↓, 1,   DNA-PK↓, 1,   DNMT1↓, 1,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

FBXW7↝, 1,   HDAC4↓, 1,   IGF-1R↓, 1,  

Migration ⓘ

EphB4↓, 1,   GnT-V↝, 1,   heparanase↝, 1,   NM23↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

FLT4↓, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,  

Cellular Microenvironment ⓘ

PLC↓, 1,  

Clinical Biomarkers ⓘ

HEC1↓, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

IMPDH1↓, 1,   IMPDH2↓, 1,  
Total Targets: 32

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IMPDH2, inosine monophosphate dehydrogenase 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:411  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page